Merida’s lead asset, MER511, is in Phase 1 for Graves’ disease and thyroid eye disease; early data showed robust reductions in pathogenic antibodies.
The pipeline also includes preclinical MER769 for allergic diseases, with earlier-stage programs targeting kidney and other immune-mediated conditions.
Closing is expected in the fourth quarter of 2026, subject to regulatory approvals and other customary conditions.
Lilly agrees to acquire Merida Biosciences
Eli Lilly agreed to acquire Merida Biosciences for up to USD 2.88 billion in cash, including upfront and milestone payments.
The deal adds Merida’s antibody-degradation platform, aimed at selectively removing disease-causing antibodies while preserving normal immune function.
LLY•
